Cagrilintide 5mg + Sema 5mg
Cagrilintide 5mg + Sema 5mg
Combines semaglutide, a GLP-1 receptor agonist approved (as Ozempic/Wegovy) for type 2 diabetes and chronic weight management, with cagrilintide, a long-acting amylin receptor agonist studied in clinical trials for additive weight loss when co-administered with GLP-1 therapy.
$ 170
FOR LABORATORY / RESEARCH USE ONLY. Not for human use or consumption. Not for animal or veterinary use or testing. Not a drug, food, cosmetic, or medical device, and not evaluated or approved by the FDA. Compounded/blended combinations of these APIs are not FDA-approved products; the approved combination product (marketed abroad as Cagrisema) is only available through a licensed prescriber.
